Metformin News and Research

RSS

Metformin is the active ingredient in a drug used to treat diabetes mellitus (a condition in which the body cannot control the level of sugar in the blood). It is also being studied in the treatment of cancer. It decreases the amount of glucose (a type of sugar) released into the bloodstream from the liver and increases the body’s use of the glucose. Metformin is a type of antidiabetic agent.

Adherence to second-line drugs for Type 2 diabetes can be hit or miss, study reports

Most patients with Type 2 diabetes will end up needing to add a second-line medication after metformin -; the go-to primary drug for glucose management -; to control their blood sugar levels.

12 Dec 2023

The influence of vitamin supplementation on longitudinal patterns of maternal vitamin status from preconception to post-delivery

Researchers secondary analyzed the NiPPeR randomized clinical trial (RCT) data to assess maternal vitamin levels pre-conception, during pregnancy, and post-delivery and also explored the impact of vitamin supplementation before and during gestation.

11 Dec 2023

A class of diabetes medications may reduce the risk of colorectal cancer

A groundbreaking study by researchers at Case Western Reserve University suggests a class of medications used to treat type 2 diabetes may also reduce the risk of colorectal cancer (CRC).

7 Dec 2023

Simple bean diet intervention demonstrates significant prebiotic effects

The impact of incorporating canned navy beans into the regular diet for eight weeks.

5 Dec 2023

Brown seaweed emerges as a potent ally in diabetes control

A study in the journal Nutrients found that brown seaweed consumption (BSC) effectively manages type 2 diabetes (T2D) risk and regulates blood glucose levels in patients.

4 Dec 2023

New adaptive clinical trial aims to reverse neurological damage caused by progressive multiple sclerosis

The first-ever adaptive clinical trial for Australians living with MS will seek to reverse neurological damage caused by progressive multiple sclerosis.

4 Dec 2023

Hevolution-AFAR New Investigator Awards expanded with $16 million grant

The American Federation for Aging Research (AFAR), is pleased to announce a $16 million expansion of the Hevolution-AFAR New Investigator Awards in Aging Biology and Geroscience Research, a grant program to enable early-career investigators with labs in the US and Canada to research healthspan-expanding therapeutics and treatments.

1 Dec 2023

New study reveals increased cancer risk linked to higher BMI in adults with cardiovascular diseases

The joint and individual correlations of CVD/T2D and BMI with cancer risk.

23 Nov 2023

Probiotics paired with metformin could be a game-changer in type 2 diabetes control

Probiotic supplementation shows promise in managing type 2 diabetes by improving glycemic control, particularly when combined with metformin, although results vary based on probiotic composition and regimen.

6 Nov 2023

Citrus compounds show zesty promise in type 2 diabetes management

Citrus compounds show promise in type 2 diabetes management, reducing blood glucose and mitigating metabolic complications without a clear threshold in humans for bioflavonoid efficacy.

2 Nov 2023

Stopping metformin early linked to higher dementia risk in older adults with type 2 diabetes

Early termination of metformin treatment in older adults with type 2 diabetes is associated with a higher risk of dementia, according to a cohort study. The research has significant implications for diabetes management, especially among those at higher risk for dementia.

29 Oct 2023

NF-κB activation during COVID-19 and its impact on patients with hypertension

Researchers review the role of NF-κB activation in the replication of SARS-CoV-2 and the impact of COVID-19 medications on NF-κB activation.

25 Oct 2023

Study highlights ways to identify children at high risk of type 2 diabetes and prevention strategies

A new Journal of the Endocrine Society study highlights how to identify children at high risk of developing type 2 diabetes and strategies for prevention, such as anti-obesity or anti-diabetes medication and lifestyle changes.

12 Oct 2023

International report paves way for precision diabetes medicine breakthrough

Precision medicine for prevention, diagnosis, treatment, and prognosis for Diabetes.

9 Oct 2023

Early metformin therapy falls short in curbing gestational diabetes woes

In a significant randomized clinical trial, early metformin therapy was tested for its potential to lessen insulin dependence and enhance glycemic control in gestational diabetes-afflicted pregnant women; however, it yielded no improvements in diabetes symptoms. While metformin reduced maternal weight gain, its effects on primary diabetes symptoms and other secondary outcomes like infant weight gain were mixed, indicating a need for further focused research to unravel these associations.

4 Oct 2023

Could a mushroom-derived product be the future of lung cancer prevention?

Researchers find that a mushroom-derived product, GLSF, shows promise in reducing lung toxicity and tumor development induced by tobacco smoke carcinogens in mice. The study opens the door for future clinical trials, potentially offering a natural preventive measure against lung cancer.

26 Sep 2023

Breast cancer patients treated with alpelisib have elevated rates of high blood sugar

New research has uncovered elevated rates of high blood sugar, or hyperglycemia, among patients with breast cancer who are treated with the oral medication alpelisib.

25 Sep 2023

Could metformin be a game changer for heart health in non-diabetics?

Using Mendelian randomization, researchers found that altering seven metformin targets led to improved blood pressure and BMI in non-diabetic individuals. The study suggests the potential for metformin's role in reducing cardiovascular risks in the general population, although more research is needed.

24 Sep 2023

Ketogenic dietary intervention may inhibit onset and progression of neuroendocrine tumors

A recent Cell Death and Disease study evaluated the effect of ketogenic dietary intervention on neuroendocrine tumors.

12 Sep 2023

Buck Institute receives $3.5 million federal grant to lead clinical trial of ketone intervention in older adults

The Buck Institute for Research on Aging has received a $3.5 million federal grant to lead the first-ever double-blind, randomized, placebo-controlled clinical trial to understand the effects of ketone ester supplementation on frailty, a condition of vulnerability which develops following age-related decline in multiple physiological systems.

11 Sep 2023